Thermo Fisher Scientific (TMO) Cash & Current Investments (2009 - 2026)

Thermo Fisher Scientific has reported Cash & Current Investments for 18 years, with the latest figure at $4.1 billion in Q2 2026.

• Cash & Current Investments for Q2 2026 came in at $4.1 billion, down 36.4% year-over-year; the trailing twelve-month figure through Jun 2026 was $4.1 billion (down 36.4% YoY), and the FY2025 annual result was $10.1 billion, up 81.42% from the prior year.
• Cash & Current Investments advanced to $4.1 billion in Q2 2026, from $3.3 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.1 billion in Q4 2025 and troughed at $1.9 billion in Q3 2022.
• A 5-year average of $5.5 billion and a median of $5.8 billion in 2024 frame the typical range for Cash & Current Investments.
• The widest annual swing landed in 2022, when Cash & Current Investments tumbled 75.73%; it then soared 181.62% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $8.5 billion in 2022, then declined by 5.21% to $8.1 billion in 2023, then plunged by 31.06% to $5.6 billion in 2024, then surged by 81.42% to $10.1 billion in 2025, then plunged by 59.78% to $4.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $4.1 billion in Q2 2026, $3.3 billion in Q1 2026, and $10.1 billion in Q4 2025.